JPRN-jRCT2041230047招募中3 期
Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors(NN7769-4532) - FRONTIER 4
Esaki Risa0 个研究点目标入组 425 人开始时间: 2023年6月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 425
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Informed consent obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- •2.Male or female with diagnosis of congenital haemophilia A based on medical records.
- •3.Ongoing participation in study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769 4728 at the time of transfer. Participant should qualify either of the following criteria:
- •a.Participant from study NN7769-4513, who has participated in the extension part of the study for at least 12 weeks prior to enrolment in study NN7769-4532, or,
- •b.Participant has completed the end of treatment visit for study NN7769-4514, NN7769 4516, or NN7769-4728.
- •4.Participant and/or participant's parent(s)/participant's legally acceptable representative (LAR) willingness and ability to comply with scheduled visits and study procedures, including the completion of diary.
排除标准
- •1.Any disorder, except for conditions associated with haemophilia, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
- •2.Participant who has discontinued or been withdrawn from studies NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728.
- •3.Previous participation in this study. Participation is defined as signed informed consent.
- •4.Female who is pregnant, breast-feeding or intends to become pregnant.
- •5.Female of child-bearing potential and not using a highly effective contraceptive method (highly effective contraceptive measures as defined in Appendix 4 or as required by local regulation or practice).
- •6.Participation (i.e., signed informed consent) in any interventional, clinical study (except from study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728) of an approved or non-approved investigational medicinal product.
- •7. Any planned majors surgery, during part1 of the study, For definition of major surgery see Table6-7.
- •8.Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.
研究者
相似试验
进行中（未招募）
Unknown
A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4)Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanismKCT0008901ovo Nordisk29
招募中
3 期
A research study looking at long-term treatment withMim8 in people with haemophilia ACTRI/2024/02/062683ovo Nordisk A/S
已完成
1 期
Open label, efficacy and safety study of long-term 6-methylsulfinylhexyl Isothiocyanate(6-MSITC) administration to Duchenne muscular dystrophyDuchenne muscular dystrophyJPRN-UMIN000033016Kobe University3
招募中
3 期
An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with HemophiliaA or B.CTRI/2019/07/020239Genzyme Corporation
已完成
3 期
ong-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IXHemophiliaJPRN-jRCT2080225111Sanofi K.K.244